{
    "2018-02-20": [
        [
            {
                "time": "",
                "original_text": "复星医药：CD20靶点利妥昔单抗类似药纳入优先审评，上市步伐加快",
                "features": {
                    "keywords": [
                        "复星医药",
                        "CD20靶点",
                        "利妥昔单抗",
                        "类似药",
                        "优先审评",
                        "上市步伐"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}